文献速递中医内科中药与中成药合理使用

丹红注射液经局部与远端β肾上腺素受体信号逆转脑心综合征心脏异常

Danhong Injection Reversed Cardiac Abnormality in Brain-Heart Syndrome via Local and Remote β-Adrenergic Receptor Signaling.
PubMed 文献 · Front Pharmacol · 2018-07-03

研究在大鼠脑缺血再灌注模型中评价丹红注射液(DHI)对脑心综合征的作用及机制。DHI 每日两次静脉给药共 14 天,可缩小梗死体积、改善神经功能,并逆转异常动脉血压与心律。机制涉及抑制β肾上腺素通路及蛋白激酶C epsilon(PKCε)。

要点

  • DHI 在大鼠脑缺血再灌注模型中显示抗卒中作用并改善神经功能缺损。
  • DHI 可逆转脑心综合征的异常动脉血压和心律。
  • DHI 的心脏保护机制与抑制β肾上腺素通路及 PKCε 相关。

核心结论

  • DHI 可能通过靶向肾上腺素通路调节心脏功能,为脑心综合征提供治疗选择。

研究设计与样本

  • 研究在 Wistar 大鼠中诱导缺血/再灌注,静脉给予 DHI 每日两次共 14 天。
  • 评估神经状态、梗死体积、CT、动脉血压、心律和血流动力学,并行脑与心肌免疫组化和 Western blot。

主要发现

  • DHI 缩小梗死体积(与溶媒组比较 ∗∗p < 0.01 和 ∗∗∗p < 0.001)。
  • DHI 改善神经功能缺损(与溶媒组比较 ∗p < 0.05 和 ∗∗∗p < 0.001)。
  • DHI 逆转异常动脉血压(与溶媒组比较 ∗p < 0.05)和心律(与溶媒组比较 ∗∗p < 0.01)。
  • DHI 抑制β肾上腺素通路及 PKCε(与模型组比较 ∗∗p < 0.01)。

关键数值与推荐

  • DHI 给药方案为静脉注射、每日两次、连续 14 天。
  • 梗死体积与神经功能缺损的组间比较采用 ∗p < 0.05、∗∗p < 0.01、∗∗∗p < 0.001 表示。

临床怎么用

  • 对缺血性卒中合并心脏功能异常者,可考虑 DHI 的多靶点潜力,但需临床研究验证。
  • DHI 可能通过肾上腺素通路影响心脏功能,用药时需关注血压与心律变化。

局限性

  • 研究为 Wistar 大鼠缺血/再灌注模型,结论外推至临床需谨慎。
  • 原文摘要未报告样本量、具体剂量及部分统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ischemic brain injury impacts cardiac dysfunction depending on the part of the brain affected, with a manifestation of irregular blood pressure, arrhythmia, and heart failure. Generally called brain-heart syndrome in traditional Chinese medicine, few mechanistic understanding and treatment options are available at present. We hypothesize that considering the established efficacy for both ischemic stroke and myocardial infarction (MI), Danhong injection (DHI), a multicomponent Chinese patent medicine, may have a dual pharmacological potential for treating the brain-heart syndrome caused by cerebral ischemic stroke through its multi-targeted mechanisms. We investigated the role of DHI in the setting of brain-heart syndrome and determined the mechanism by which it regulates this process. We induced Ischemia/Reperfusion in Wistar rats and administered intravenous dose of DHI twice daily for 14 days. We assessed the neurological state, infarct volume, CT scan, arterial blood pressure, heart rhythm, and the hemodynamics. We harvested the brain and heart tissues for immunohistochemistry and western blot analyses. Our data show that DHI exerts potent anti-stroke effects (infarct volume reduction: ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. vehicle. Neurological deficit correction: ∗p < 0.05 and ∗∗∗p < 0.001 vs. vehicle), and effectively reversed the abnormal arterial pressure (∗p < 0.05 vs. vehicle) and heart rhythm (∗∗p < 0.01 vs. vehicle). The phenotype of this brain-heart syndrome is strikingly similar to those of MI model. Quantitative assessment of hemodynamic in cardiac functionality revealed a positive uniformity in the PV-loop after administration with DHI and valsartan in the latter. Immunohistochemistry and western blot results showed the inhibitory effect of DHI on the β-adrenergic pathway as well as protein kinase C epsilon (PKCε) (∗∗p < 0.01 vs. model). Our data showed the underlying mechanisms of the brain-heart interaction and offer the first evidence that DHI targets the adrenergic pathway to modulate cardiac function in the setting of brain-heart syndrome. This study has made a novel discovery for proper application of the multi-target DHI and could serve as a therapeutic option in the setting of brain-heart syndrome.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Orgah JO, Yu J, Zhao T, et al. Danhong Injection Reversed Cardiac Abnormality in Brain-Heart Syndrome via Local and Remote β-Adrenergic Receptor Signaling. Front Pharmacol. 2018. PMID: 30018549. doi:10.3389/fphar.2018.00692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。